Incidence and clinical characteristics of myeloproliferative neoplasms displaying a PDGFRB rearrangement

European Journal of Haematology

Volumn 89, Issue 1, 2012, Pages 37-41

  Arefi, Maryam ^a   García, Juan L ^b   Peñarrubia, María J ^a   Queizán, José A ^c   Hermosín, Lourdes ^d   López Corral, Lucía ^e   Megido, Marta ^f   Giraldo, Pilar ^g   de las Heras, Natalia ^h   Vanegas, Raúl J ⁱ   Gutiérrez, Norma C ^e   Hernández Rivas, Jesús M ^b,e,j  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b Instituto de Ciencias de la Salud de Castilla y León IESCYL   (Spain)

^c HOSPITAL GENERAL DE SEGOVIA   (Spain)

^d Hospital del SAS   (Spain)

^e HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^f Hospital Camino de Santiago   (Spain)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^h Hospital Virgen Blanca   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^j UNIVERSITY OF SALAMANCA   (Spain)

more..

Author keywords

Atypical CML (aCML); Chronic myelomonocytic leukaemia (CMML); Cytogenetics; Fluorescence in situ hybridisation (FISH); Myeloproliferative neoplasms (MPNs); PDGFRB rearrangement

Indexed keywords

IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW CELL; CANCER INCIDENCE; CELL INFILTRATION; CLINICAL FEATURE; CYTOGENETICS; DISEASE ASSOCIATION; EOSINOPHILIA; FEMALE; FOLLOW UP; GENE REARRANGEMENT; GENE TRANSLOCATION; HUMAN; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MYELOPROLIFERATIVE NEOPLASM; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BONE MARROW NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INCIDENCE; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TRANSLOCATION, GENETIC; TREATMENT OUTCOME;

EID: 84862571219     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2012.01799.x     Document Type: Article

References (21)

1. Tefferi A. Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1. J Cell Mol Med 2009;13:215-37.
2. Wadleigh M, Tefferi A. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria. Int J Hematol 2010;91:174-9.
3. Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009;115:3842-7.
4. Cross NC, Reiter A. Tyrosine Kinase fusion genes in chronic myeloproliferative disease. Leukemia 2002;16:1207-12.
5. Walz C, Metzgeroth G, Haferlach C, et al. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Haematologica 2007;92:163-9.
6. Golub TR, Barker GF, Lovett M, Gilliland DG. Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 1994;77:307-16.
7. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative disease with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-7.
8. Baxter EJ, Kulkarni S, Vizmanos JL, et al. Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders. Br J Haematol 2003;120:251-6.
9. Jones AV, Cross NC. Oncogenic derivatives of platelet-derived growth factor receptors. Cell Mol Life Sci 2004;61:2912-23.
10. Reiter A, Walz C, Cross NC. Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Curr Drug Targets 2007;8:205-16.
11. Erben P, Gosenca D, Muller MC, et al. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica 2010;95:738-44.
12. Hernández JM, del Cañizo MC, Cuneo A, García JL, Gutiérrez NC, González M, Castoldi G, San Miguel JF. Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol 2000;11:441-4.
13. ISCN. In: Shaffer LG, Slovak ML, Campbell LJ, Marilyn L, Lynda J, Campbell LJ, eds. An International System for Human Cytogenetic Nomenclature. Basel: Karger Paper back; 2009: pp 1-138. ISBN 3805589859
14. Hernández JM, González MB, Granada I, Gutiérrez N, Chillón C, Ramos F, Ribera JM, González M, Feliu E, San Miguel J. Detection of inv(16) and t(16;16) by fluorescence in situ hybridization in acute myeloid leukemia M4Eo. Haematologica 2000;85:481-5.
15. Garcia JL, Font de Mora J, Hernandez JM, Queizan JA, Gutierrez NC, Hernandez JM, San Miguel JF. Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. Blood 2003;102:2699-700.
16. Pardanani A, Tefferi A. Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leuk Res 2004;28:47-52.
17. Cross NC, Reiter A. Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders. Acta Haematol 2008;119:199-206.
18. David M, Cross NC, Burgstaller S, et al. Durable responses to Imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL -negative chronic myeloproliferative disorders. Blood 2007;109:61-4.
19. Steer EJ, Cross NCP. Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta. Acta Haematol 2002;107:113-22.
20. Lierman E, Cools J. TV6 and PDGFRB: a license to fuse. Haematologica 2007;92:145-7.
21. Yagasaki F, Jinnai I, Yoshida S, et al. Fusion of TEL/ETV6 to a novel ACS2 in myelodysplastic syndrome and acute myelogenous leukaemia with t(5;12)(q31;p13). Genas Chromosomes Cancer 1999;26:192-202.